Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Rose, Witter"'
Autor:
Jacqueline B. McCrea, Karsten Menzel, Craig Fancourt, Rose Witter, Tian Zhao, Jonathan A. Robbins, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee250d387be2feea885d36e641eaf58d
https://doi.org/10.1111/bcp.15677
https://doi.org/10.1111/bcp.15677
Autor:
Karsten Menzel, Jacqueline B. McCrea, Craig Fancourt, Rose Witter, Tian Zhao, S. Aubrey Stoch, Marian Iwamoto
Publikováno v:
British journal of clinical pharmacology.
Letermovir inhibits renal tubular organic anion transporter (OAT)3 in vitro and is predicted to inhibit OAT3 in vivo. Acyclovir, a substrate for OAT3, is likely to be co-administered with letermovir; therefore, letermovir may increase acyclovir conce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10d6077a0a0dfaa1b64a10747a287c05
https://pubmed.ncbi.nlm.nih.gov/36537620
https://pubmed.ncbi.nlm.nih.gov/36537620
Autor:
Stefan Zajic, Monika Martinho, Julie A. Stone, Rose Witter, S. Aubrey Stoch, Jacqueline B. McCrea, Ghassan N. Fayad
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 47:473-484
To develop a framework for evaluating the resorption effects of Cathepsin K (CatK) inhibitors and to inform dose regimen selection, a pharmacokinetic/pharmacodynamic (PK/PD) model for odanacatib (ODN) was developed based upon data from Phase 1 studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2579f2a12080ca35578197a5aabeec8c
https://doi.org/10.1007/s10928-020-09699-9
https://doi.org/10.1007/s10928-020-09699-9
Publikováno v:
Br J Clin Pharmacol
Cathepsin K (CatK) is a cysteine protease abundantly expressed by osteoclasts and localized in the lysosomes and resorption lacunae of these cells. CatK is the principal enzyme responsible for the degradation of bone collagen. Odanacatib is a selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac9d30ac61e9d70d3a9c1def79b9302
https://doi.org/10.1111/bcp.13869
https://doi.org/10.1111/bcp.13869
Autor:
Jonathan A. Robbins, Karsten Menzel, Michael Lassman, Tian Zhao, Craig Fancourt, Xiaoyan Chu, Kate Mostoller, Rose Witter, Rachel Marceau West, S. Aubrey Stoch, Jacqueline B. McCrea, Marian Iwamoto
Publikováno v:
Clinical pharmacology and therapeutics. 111(3)
Rifampin has acute inhibitory and chronic inductive effects that can cause complex drug-drug interactions. Rifampin inhibits transporters including organic-anion-transporting polypeptide (OATP)1B and P-glycoprotein (P-gp), and induces enzymes and tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a23c659a1834910d2214932ed5305b
https://pubmed.ncbi.nlm.nih.gov/34888851
https://pubmed.ncbi.nlm.nih.gov/34888851
Autor:
Christine Brandquist, S. Aubrey Stoch, Rose Witter, Cynthia Dempsey, Christopher R. Gibson, Filippos Kesisoglou, Stefan Zajic, Marc L. Reitman, Jeanine E. Ballard, Daria Stypinski, Kelem Kassahun, Anish Mehta
Publikováno v:
The Journal of Clinical Pharmacology. 57:110-117
This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e300cabf64e7659f28ba32a7feefb6ea
https://doi.org/10.1002/jcph.780
https://doi.org/10.1002/jcph.780
Autor:
Rose Witter, David Hreniuk, Filippos Kesisoglou, Roy Helmy, Stefan Zajic, Julie A. Stone, Darrick Joss, S. Aubrey Stoch, Don Gauthier, Stefaan Rossenu, Tong Ni, Fang Liu, Li Sun, Randall Stoltz, Jacqueline B. McCrea
Publikováno v:
Drug Metabolism and Disposition. 44:1450-1458
A stable-label i.v./oral study design was conducted to investigate the pharmacokinetics (PK) of odanacatib. Healthy, postmenopausal women received oral doses of unlabeled odanacatib administered simultaneously with a reference of 1 mg i.v. stable (13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2906899c0c7e5d982b75e0cfa706575
https://doi.org/10.1124/dmd.116.069906
https://doi.org/10.1124/dmd.116.069906
Autor:
Eric Mangin, Ji Jiang, Fang Liu, Rose Witter, Pei Hu, Xia Chen, Stefan Zajic, Wen Liu, S. Aubrey Stoch, Jacqueline B. McCrea
Publikováno v:
Clinical pharmacology in drug development. 7(7)
Odanacatib (ODN), an oral selective inhibitor of cathepsin K, was an investigational agent previously in development for the treatment of osteoporosis. In this phase 1 open-label study, 12 healthy Chinese postmenopausal women received single-dose ODN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c3dcd5cbcb29e5dfde8c0f0436c8eb
https://pubmed.ncbi.nlm.nih.gov/29443463
https://pubmed.ncbi.nlm.nih.gov/29443463
Autor:
Christine Brandquist, David Hreniuk, Anish Mehta, Bruce DeGroot, Rose Witter, S. Aubrey Stoch, Cynthia Dempsey, Stefan Zajic, Andrew Denker, Daria Stypinski, Chengcheng Liu, John A. Wagner
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 51:688-692
OBJECTIVES This study was conducted in order to assess the effect of multiple doses of odanacatib, a cathepsin (Cat)-K inhibitor, on the pharmacokinetics of digoxin. MATERIALS Twelve healthy male and female subjects received 0.5 mg digoxin and 50 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02f1e59edb33df2b81fdf2ccae160df4
https://doi.org/10.5414/cp201864
https://doi.org/10.5414/cp201864
Autor:
S Aubrey, Stoch, Jeanine, Ballard, Christopher, Gibson, Filippos, Kesisoglou, Rose, Witter, Kelem, Kassahun, Stefan, Zajic, Anish, Mehta, Christine, Brandquist, Cynthia, Dempsey, Daria, Stypinski, Marc L, Reitman
Publikováno v:
Journal of clinical pharmacology. 57(1)
This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a0c501d98dd862901e63a1275a9600c8
https://pubmed.ncbi.nlm.nih.gov/27321774
https://pubmed.ncbi.nlm.nih.gov/27321774